drugset / Trial / NCT06099366
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
Phase 2
Recruiting
116 enrolled
Hee Young Ju
Asan Medical Center · collabChonnam National University Hospital · collabJeju National University Hospital · collabKorea University Anam Hospital · collabPusan National University Yangsan Hospital · collabSeoul National University Hospital · collabSeoul St. Mary's Hospital · collabSeverance Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.
Timeline
- Start
- 2024-03-05
- Primary completion
- 2033-12-31
- Completion
- 2033-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 75 mg/m2 | Intrathecal |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intrathecal |
| Subject | Dexamethasone | Small molecule | 6 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 10 mg/m2 | — |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 25 mg/m2 | — |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 50 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | — |
| Background | Methotrexate | Small molecule | 20 mg/m2 | Intrathecal |
| Background | Methotrexate | Small molecule | 5000 mg/m2 | Intrathecal |
| Background | Vincristine | Small molecule | 1.5 mg/m2 | — |
| Background | asparaginase | Protein / enzyme biologic | 6000 unknown | — |